New study checks if maribavir works safely for transplant patients with stubborn CMV
NCT ID NCT06213974
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study follows about 10 adults and children (12 years and older) in Argentina who have a CMV infection after an organ transplant that did not get better with standard treatments. Researchers will track how well maribavir works and what side effects occur during routine care. The goal is to see if the drug is safe and effective in real-world use.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CYTOMEGALOVIRUS (CMV) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
IC Projects
RECRUITINGCity of Buenos Aires, C11119ACN, Argentina
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Better CMV detection for IBD patients: which test works best?
- New hope for young transplant patients: maribavir trial targets CMV
- New trial aims to stop CMV eye inflammation from returning
- New hope for transplant patients with Drug-Resistant CMV
- Maribavir safety under review for kidney patients with CMV
- UK study digs into CMV infection patterns in kidney transplant patients